Evolutionary Genomics Inc (FNAM) |
|
Price: $0.4500
$-0.15
-25.000%
|
Day's High:
| $0.45
| Week Perf:
| -30.77 %
|
Day's Low: |
$ 0.45 |
30 Day Perf: |
|
Volume (M): |
0 |
52 Wk High: |
$ 0.72 |
Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.63 |
Open: |
$0.45 |
52 Wk Low: |
$0.45 |
|
|
Market Capitalization (Millions $) |
3 |
Shares
Outstanding (Millions) |
6 |
Employees |
- |
Revenues (TTM) (Millions $) |
- |
Net Income (TTM) (Millions $) |
-2 |
Cash Flow (TTM) (Millions $) |
0 |
Capital Exp. (TTM) (Millions $) |
0 |
Evolutionary Genomics Inc
Evolutionary Genomics Inc is a biotechnology company specializing in evolutionary genomics research and analysis. It applies genomic technologies and computational algorithms to study the genetic variation and evolutionary history of various species, including humans, animals, and plants.
The company aims to improve the understanding of genetic diversity, adaptation, and evolutionary processes by analyzing large-scale genomic datasets. It develops advanced bioinformatics tools and algorithms to decipher the complex genetic code and identify key genomic variations that drive evolutionary changes.
Evolutionary Genomics Inc collaborates with academic institutions, research centers, and pharmaceutical companies to provide genomics services and assist in uncovering important genetic insights. Its services include genotyping, whole-genome sequencing, comparative genomics analysis, and evolutionary modeling.
The company's research findings and genomic discoveries have practical applications in various fields, including medicine, conservation biology, agriculture, and evolutionary biology. Its work contributes to the development of personalized medicine, conservation strategies, crop improvement, and understanding the fundamental processes that shape biodiversity.
Overall, Evolutionary Genomics Inc plays a crucial role in advancing our understanding of genetics, evolution, and their implications in various domains, with the aim of making significant contributions to scientific knowledge and practical applications in genomics research.
Company Address: 4220 Morning Star Drive Castle Rock 80108 CO
Company Phone Number: 900-8666 Stock Exchange / Ticker: FNAM
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Exagen Inc
Exagen Inc (Nasdaq: XGN) has shown significant signs of weakness in its latest financial report for the fourth quarter of 2023. Despite a decrease in the loss per share compared to the previous year, the company still reported a loss of $-0.30 per share. This is only a slight improvement from the loss of $-0.83 per share in the same period a year prior. Although there was a 7.229% increase in revenue to $13.77 million from $12.84 million in the corresponding reporting season, this is a relatively small growth rate and not enough to inspire confidence in the company's prospects. The sequential revenue growth of 2.601% from $13.42 million is also modest at best.
|
Enzo Biochem Inc
Enzo Biochem Inc, a medical laboratories company, experienced a stable stock performance in March 2024 with no change in its share price. However, this brings the share price to a decrease of 11.33% in the first quarter of 2024. Additionally, the stock is currently trading only 33% above its 52-week low. For the financial second quarter of 2024, Enzo Biochem Inc reported a significant improvement in its earnings per share (EPS) compared to the previous year. The loss per share decreased from $-0.23 to $-0.06. Furthermore, the EPS also improved from the preceding quarter, going from $-0.13 to $-0.06.
|
Ispecimen Inc
iSpecimen Inc. (Nasdaq: ISPC) is a pioneering online marketplace that connects scientists with healthcare specimen providers for research purposes. The company, headquartered in Lexington, Massachusetts, has recently announced that it will unveil its full-year financial results for the period ending December 31, 2023, on March 13, 2024. Stakeholders are eagerly awaiting the release of these results, as iSpecimen is globally recognized for its innovative platform that facilitates breakthrough discoveries and accelerates scientific advancements. The previous fiscal span, from October to December 31, 2023, saw iSpecimen Inc. experience a deficit per share of $-0.33, compared to $-0.20 the previous year. This represents a growth in deficit per share from $-0.23 from the prior reporting season. Additionally, the company's revenue declined by -13.049% to $2.58 million from $2.96 million in the comparable reporting season a year before. Sequentially, revenue deteriorated by -7.296% from $2.78 million.
|
Maxcyte Inc
Maxcyte Inc, a leading cell-engineering focused company, recently announced its fourth quarter and full year financial results for 2023. The company reported a surge in revenue by 26.087% to $15.66 million from the same reporting period a year before. However, it also experienced diminishing returns with a net shortfall of $-0.05 per share. Despite the positive revenue growth, Maxcyte Inc's shares have gone down by -15.63% in the past 5 trading days and -14.35% from a year ago. Currently, the company's shares are trading on the NASDAQ by -8.4% below its 52 week average.
|
Butterfly Network Inc
Butterfly Network Inc Reports Decreased Loss Per Share, Declining Revenue for Q4 2023 BURLINGTON, Mass. and NEW YORK - Butterfly Network, Inc. (NYSE: BFLY), a digital health company focused on portable, semiconductor-based ultrasound technology, announced its financial results for the quarter and year ended December 31, 2023. The company also provided an update on its business activities. Butterfly Network aims to make medical imaging more accessible through its innovative product offerings, software solutions, and educational programs. For the financial period closing December 31, 2023, Butterfly Network reported a loss of $-0.21 per share, showing an improvement from the loss of $-0.31 per share in the previous year. However, there was an increased loss compared to the previous reporting period, from $-0.13 per share. The company's revenue declined by 14.346% to $17.08 million from $19.94 million, in the comparable reporting period a year prior. Nevertheless, sequentially, the revenue advanced by 11.013%, from $15.38 million.
|
Per Share |
Current |
Earnings (TTM) |
-0.34 $ |
Revenues (TTM) |
-
|
Cash Flow (TTM) |
0.06 $ |
Cash |
0.09 $
|
Book Value |
-
|
Dividend (TTM) |
0 $ |
|
Per Share |
|
Earnings (TTM) |
-0.34 $
|
Revenues (TTM) |
- |
Cash Flow (TTM) |
0.06 $ |
Cash |
0.09 $
|
Book Value |
- |
Dividend (TTM) |
0 $ |
|
|
|
|